Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Sciulli MG et al. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. 2006 Clin. Pharmacol. Ther. pmid:16890573
Shi T et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. 2006 Arthritis Rheum. pmid:16868978
Ramamurthy S et al. Characterization of thromboxane A2 receptor signaling in developing rat oligodendrocytes: nuclear receptor localization and stimulation of myelin basic protein expression. 2006 J. Neurosci. Res. pmid:16998891
Zhou Y et al. Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice. 2006 Circ. Res. pmid:16645140
Karkabounas S et al. Anticarcinogenic and antiplatelet effects of carvacrol. 2006 Exp. Oncol. pmid:16837902
Wilder-Smith CH et al. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. 2006 Scand. J. Gastroenterol. pmid:16497612
Brenneis C et al. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. 2006 FASEB J. pmid:16816110
Baltzer WI et al. Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus. 2006 Am. J. Vet. Res. pmid:16426215
Chiu HF et al. Mechanisms involved in the antiplatelet effect of C-phycocyanin. 2006 Br. J. Nutr. pmid:16469164
Rossoni G et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. 2006 Pharmacol. Res. pmid:16488624
Lepäntalo A et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. 2006 Thromb. Haemost. pmid:16493486
Kurosawa S et al. Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy. 2006 J Clin Anesth pmid:16517327
Ibrahim S et al. Transfer of very low density lipoprotein-associated phospholipids to activated human platelets. 2006 J. Lipid Res. pmid:16293890
Friton GM et al. Clinical and anti-inflammatory effects of treating endotoxin-challenged pigs with meloxicam. 2006 Vet. Rec. pmid:17056651
Ma K et al. [Study on comparative pharmacology of series of Muskone]. 2006 Zhongguo Zhong Yao Za Zhi pmid:17061560
Myers SI et al. Oxygen-radical regulation of renal blood flow following suprarenal aortic clamping. 2006 J. Vasc. Surg. pmid:16520177
Fu JH et al. [Protective effects of saponines of stem and leaf of Panax notoginseng on acute myocardial ischemia in anaesthetic dogs]. 2006 Zhongguo Zhong Yao Za Zhi pmid:16548173
Kanazawa S et al. Aspirin reduces adverse effects of gefitinib. 2006 Anticancer Drugs pmid:16550000
Lee KS et al. Anti-platelet activity of KR-32560, a novel sodium/hydrogen exchanger-1 inhibitor. 2006 Pharmacol. Res. pmid:16420980
Yin M et al. [Experimental study of effects of cyclooxygenase-2 inhibitor on apoptosis of hypoxic myocardial cells in vitro]. 2006 Zhongguo Wei Zhong Bing Ji Jiu Yi Xue pmid:16647015
Ahmad S et al. Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood. 2006 Eur. J. Pharmacol. pmid:16650843
Fontana P et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. 2006 J. Thromb. Haemost. pmid:16634751
Markuszewski L et al. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? 2006 Basic Clin. Pharmacol. Toxicol. pmid:16635110
Cheung PY et al. Platelet dysfunction in asphyxiated newborn piglets resuscitated with 21% and 100% oxygen. 2006 Pediatr. Res. pmid:16627873
Laleman W et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. 2006 Eur. J. Clin. Invest. pmid:16620286
Zhao Y et al. Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis. 2006 Ann. Allergy Asthma Immunol. pmid:16802773
Lee KS et al. Antiplatelet activity of [5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl]guanidine (KR-32570), a novel sodium/hydrogen exchanger-1 and its mechanism of action. 2006 Arch. Pharm. Res. pmid:16756082
Peck OM et al. The phosphatidylinositol 3 kinase pathway regulates tolerance to lipopolysaccharide and priming responses to Staphylococcus aureus and lipopolysaccharide. 2006 Shock pmid:16783195
Frelinger AL et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. 2006 Circulation pmid:16785341
Cox D et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. 2006 Stroke pmid:16794200
Munsterhjelm E et al. Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. 2006 Br J Anaesth pmid:16698862
Eligini S et al. Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. 2006 Cardiovasc. Res. pmid:16154551
Nobutoki T et al. Fluctuating hearing loss, episodic headache, and stroke with platelet hyperaggregability: coexistence of auditory neuropathy and cochlear hearing loss. 2006 Brain Dev. pmid:16168600
Zhang JY et al. [Study on therapeutic effects of series of muskone on myocardial infarction canines]. 2006 Zhongguo Zhong Yao Za Zhi pmid:17225541
Basili S et al. Insulin resistance as a determinant of platelet activation in obese women. 2006 J. Am. Coll. Cardiol. pmid:17174194
Hrushka NH et al. [Effect of thromboxane B2 on morphological features of apoptosis in cultured rat hepatocytes exposed to hepatotropic substances]. 2006 Fiziol Zh pmid:17176837
Niemi TT et al. The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. 2006 Blood Coagul. Fibrinolysis pmid:16607076
Chiang N and Serhan CN New mechanism for an old drug: aspirin triggers anti-inflammatory lipid mediators with gender implications. 2006 Compr Ther pmid:17435267
Michel F et al. Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization. 2006 Arterioscler. Thromb. Vasc. Biol. pmid:16385086
Chiang N et al. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. 2006 Arterioscler. Thromb. Vasc. Biol. pmid:16293793
Wolfram RM et al. Salivary isoprostanes indicate increased oxidation injury in periodontitis with additional tobacco abuse. 2006 Biofactors pmid:17264390
González-Correa JA et al. Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood. 2005 May-Jun Platelets pmid:16011961
Ikonomidis I et al. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. 2005 Am. Heart J. pmid:15894964
Petrikova M et al. Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets. 2005 Bratisl Lek Listy pmid:15869009
Komers R et al. Renal cyclooxygenase-2 in obese Zucker (fatty) rats. 2005 Kidney Int. pmid:15882258
Sciulli MG et al. Platelet activation in patients with colorectal cancer. 2005 Prostaglandins Leukot. Essent. Fatty Acids pmid:15626589
Gonzalez-Conejero R et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? 2005 Stroke pmid:15604423
Zheng YN et al. Effects of compounds in leaves of Salix matsudana on arachidonic acid metabolism. 2005 Yakugaku Zasshi pmid:16327246
Phillips J and Pearce B Serum deprivation and re-addition: effects on cyclooxygenase inhibitor sensitivity in cultured glia. 2005 Inflammopharmacology pmid:16280096
Gambero A et al. Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors. 2005 Inflammopharmacology pmid:16280097